Lilly's Retatrutide Succeeds in Two More Phase 3 Obesity Trials, Filing Planned for 2027

Eli Lilly announced today that retatrutide has met its primary weight-loss endpoints in two additional Phase 3 obesity trials, marking a significant expansion of the drug's clinical evidence base and setting the stage for regulatory filings. The two new trials, part of the TRIUMPH clinical program, showed "significant improvements in weight and A1C" according to the company's press release. While Lilly has not yet disclosed full numerical results, the topline data confirms that retatrutide achieved statistically significant weight loss compared to placebo in both studies. These results come on top of three other positive Phase 3 readouts: TRIUMPH-1 (obesity without diabetes, up to 30.3% mean weight loss reported in May), TRIUMPH-4 (knee osteoarthritis with significant pain reduction), and TRIUMPH-2 data presented at the ADA 86th Scientific Sessions in June. With five positive Phase 3 trials now in hand, retatrutide's dossier is among the most robust ever assembled for an obesity therapeutic. ## Regulatory path forward The company confirmed it plans to file for U.S. Food and Drug Administration approval in 2027. The timeline reflects the scale of the submission package: Lilly is expected to include data from all five positive Phase 3 trials, covering obesity with and without diabetes, osteoarthritis, and potentially cardiovascular outcomes depending on when TRIUMPH-OUTCOMES reads out. For Canadians, the filing timeline is significant. Health Canada typically reviews new drug submissions (NDS) in parallel with or shortly after FDA review, especially for priority therapies. If Lilly files with Health Canada shortly after the U.S. submission, Canadian approval could follow in late 2027 or early 2028 — a timeline consistent with the earlier TRIUMPH-1 analysis on getretatrutide.ca. ## What the data show While full results have not been published, the company characterized the weight loss as "clinically meaningful" across both trials. The A1C improvements are particularly noteworthy for patients with obesity and type 2 diabetes, who represent a large segment of the treatable population. Analysts at CNBC and the Wall Street Journal have noted that the breadth of Lilly's Phase 3 program makes retatrutide a potential best-in-class or first-in-class therapy. With gastrointestinal tolerability managed through a 24-week dose-escalation schedule, the drug's profile continues to strengthen as more data accumulate. ## Canadian context For Canadians living with obesity, today's announcement is encouraging on several fronts: 1. **Approval timeline clarity:** The 2027 filing gives a concrete horizon for Health Canada submission and potential approval. 2. **Trial site participation:** The TRIUMPH program has enrolled Canadian patients at sites across the country, meaning Health Canada reviewers will have data reflective of Canadian populations. 3. **Provincial coverage pathway:** A more comprehensive Phase 3 dataset strengthens the case for formulary listing and public reimbursement once approved. However, Canadians should temper expectations about immediate access. Even after Health Canada approval, provincial drug plan reviews take additional months to years. Private insurance may cover retatrutide sooner, but the drug's ultimate price — which has not been disclosed — will determine how quickly it reaches Canadian patients. ## What to watch next The most anticipated remaining readout is TRIUMPH-OUTCOMES, a cardiovascular outcomes trial that could support retatrutide's case for cardioprotective benefits beyond weight loss. Results are expected in late 2026 or early 2027. Additionally, the head-to-head TRIUMPH-5 trial comparing retatrutide directly against semaglutide (Novo Nordisk's Wegovy/Ozempic) will provide important differentiation data. ## Sources - [CNBC: "Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials"](https://www.cnbc.com/2026/07/23/eli-lilly-retatrutide-phase-3-obesity-trials-filing-2027.html) — July 23, 2026 - [Eli Lilly press release: "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials"](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional-phase-3) — July 23, 2026 - [Wall Street Journal: "Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data"](https://www.wsj.com/health/healthcare/eli-lilly-preparing-retatrutide-applications-after-positive-weight-loss-data) — July 23, 2026 (archived) - [Investing.com Canada: "Lilly's retatrutide meets endpoints in two phase 3 obesity trials"](https://ca.investing.com/news/stock-market-news/lillys-retatrutide-meets-endpoints-in-two-phase-3-obesity-trials-4321) — July 23, 2026